Photo of Professionals at the Brandi Law Firm.

We Are Here To Help You Through Your Most Difficult Times

  1. Home
  2.  – 
  3. Drug and Medical Device Litigation
  4.  – Johnson and Johnson Again Leads Big Pharma in 2014 Revenues

Johnson and Johnson Again Leads Big Pharma in 2014 Revenues

| Mar 30, 2015 | Drug and Medical Device Litigation

J&J, who has seemingly survived the DePuy wars and is now facing down 22,000 vaginal mesh suits after losing mesh verdicts for its Ethicon product again leads the way in profits for Big Pharma in 2014, according to Tracy Staton writing in Fierce Pharma.

Click here to read the full article: The Top 15 Pharma Companies by 2014 Revenue

The top 15 list contains all of the traditional Big Pharma players: J&J, Novartis, Roche, Pfizer, Sanofi, Merck, GSK, AstraZeneca, Bayer, AbbVie, Lilly and Bristol-Myers Squibb, as well as some relative new comers: Gilead Sciences, Teva, and Amgen.  These 15 companies amassed 2014 sales of just under $527 billion.  J&J’s revenues increased by slightly more than $3 billion (4%), Roche grew by $1.3 billion (2.7%), Amgen was up by roughly $1.4 billion (7%), Bayer rose by $1.3 billion (5%), and AbbVie grew by almost $1.2 billion (5.8%).

J&J’s $74 billion was led by prescription drugs, which  brought in $32.4 billion for J&J last year, making pharma the biggest of its divisions.

CEO Alex Gorsky is well compensated for his leadership.  According to Alex Gorsky in 2013 made $15,171,960 in total compensation.  Of this total $1,453,846 was received as a salary, $4,867,361 was received as a bonus, $2,669,999 was received in stock options, $5,988,975 was awarded as stock and $191,779 came from other types of compensation.  This information is according to proxy statements filed for the 2013 fiscal year.

J& J’s litigation in DePuy is well documented as is its efforts with vaginal mesh.

Contact Our Experienced San Francisco Drug Recall Lawyers Today

At The Brandi Law Firm, we help people throughout the country who have been harmed because of a defective drug or medical device such as Actos (Takata), Fosamax (Merck), DePuy (Johnson & Johnson), Lipitor (Pfizer), Yaz (Bayer) and Vaginal Mesh (Johnson & Johnson).  Instead of treating all victims of defective drugs and medical devices the same we take a different, more personalized approach with a team of experienced defective drug attorneys and paralegals working for every client.  Our goal is to provide you with information about your legal options and to help you pursue compensation and holding these drug companies responsible for their dangerous actions.  Please contact The Brandi Law Firm today (1-800-481-1615 or email us) to talk with the experienced San Francisco defective drug attorneys.

Trademark Notice

Johnson & Johnson is a registered trademark of Johnson & Johnson Inc.  The use of this trademark is solely for product identification and informational purposes.  Johnson & Johnson Inc. is not affiliated with this website, and Johnson & Johnson Inc. has no affiliation with The Brandi Law Firm.  Nothing on this site has been authorized or approved by Johnson & Johnson Inc.